JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE) ›› 2021, Vol. 41 ›› Issue (2): 202-209.doi: 10.3969/j.issn.1674-8115.2021.02.012
• Clinical research • Previous Articles Next Articles
Xiao-bin ZHANG1(), Peng LIU2(), Zhi-chao LIU1, Yang YANG1, Bin LI1, Yi-feng SUN1, Rong HUA1, Xu-feng GUO1, Yi HE1, Hai-yong GU1, Zhi-gang LI1()
Received:
2020-05-15
Online:
2021-02-28
Published:
2021-02-28
Contact:
Zhi-gang LI
E-mail:zxb5212@163.com;liu1212peng@163.com;dr_lizhigang@163.com
Supported by:
CLC Number:
Xiao-bin ZHANG, Peng LIU, Zhi-chao LIU, Yang YANG, Bin LI, Yi-feng SUN, Rong HUA, Xu-feng GUO, Yi HE, Hai-yong GU, Zhi-gang LI. Biological characteristics and surgical treatment results of stage Ⅰ esophageal squamous cell carcinoma[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(2): 202-209.
Add to citation manager EndNote|Ris|BibTeX
URL: https://xuebao.shsmu.edu.cn/EN/10.3969/j.issn.1674-8115.2021.02.012
Variable | Total/n (%) |
---|---|
Overall complication | 155 (40.9) |
Pneumonia | 51 (13.5) |
Pleural effusion requiring additional drainage procedure | 42 (11.1) |
Pneumothorax requiring treatment | 10 (2.6) |
Respiratory failure requiring reintubation | 11 (2.9) |
Empyema | 10 (2.6) |
Cardiac arrhythmia | 8 (2.1) |
Cardiac arrest requiring cardiopulmonary resuscitation | 5 (1.3) |
Anastomotic leakage | 47 (12.4) |
Conduit necrosis | 2 (0.5) |
Tracheoesophageal fistula | 2 (0.5) |
Gastrointestinal bleeding | 1 (0.3) |
Liver dysfunction | 1 (0.3) |
Diaphragmatic hernia | 0 (0) |
Deep venous thrombosis | 0 (0) |
Pulmonary embolus | 2 (0.5) |
Recurrent nerve injury | 54 (14.2) |
Delirium | 0 (0) |
Wound infection | 4 (1.1) |
Chyle leak | 3 (0.8) |
Clavien-Dindo classification | |
Ⅰ?Ⅱ | 76 (20.1) |
Ⅲ?Ⅴ | 79 (20.8) |
Tab 1 Postoperative complications of 379 patients with stage Ⅰ esophageal cancer
Variable | Total/n (%) |
---|---|
Overall complication | 155 (40.9) |
Pneumonia | 51 (13.5) |
Pleural effusion requiring additional drainage procedure | 42 (11.1) |
Pneumothorax requiring treatment | 10 (2.6) |
Respiratory failure requiring reintubation | 11 (2.9) |
Empyema | 10 (2.6) |
Cardiac arrhythmia | 8 (2.1) |
Cardiac arrest requiring cardiopulmonary resuscitation | 5 (1.3) |
Anastomotic leakage | 47 (12.4) |
Conduit necrosis | 2 (0.5) |
Tracheoesophageal fistula | 2 (0.5) |
Gastrointestinal bleeding | 1 (0.3) |
Liver dysfunction | 1 (0.3) |
Diaphragmatic hernia | 0 (0) |
Deep venous thrombosis | 0 (0) |
Pulmonary embolus | 2 (0.5) |
Recurrent nerve injury | 54 (14.2) |
Delirium | 0 (0) |
Wound infection | 4 (1.1) |
Chyle leak | 3 (0.8) |
Clavien-Dindo classification | |
Ⅰ?Ⅱ | 76 (20.1) |
Ⅲ?Ⅴ | 79 (20.8) |
Variable | n (%) | OS | DFS | ||||
---|---|---|---|---|---|---|---|
HR | 95%CI | P value | HR | 95%CI | P value | ||
Age | 0.025 | 0.211 | |||||
<65 year | 203 (53.6) | 1.000 | ? | 1.000 | ? | ||
≥65 year | 176 (46.4) | 2.521 | 1.124?5.656 | 1.480 | 0.801?2.734 | ||
Gender | 0.092 | 0.127 | |||||
Male | 300 (79.2) | 1.000 | ? | 1.000 | ? | ||
Female | 79 (20.8) | 0.179 | 0.024?1.324 | 0.448 | 0.159?1.258 | ||
Comorbidity | 0.502 | 0.821 | |||||
None | 310 (81.8) | 1.000 | ? | 1.000 | ? | ||
Yes | 69 (18.2) | 1.400 | 0.524?3.738 | 1.098 | 0.487?2.479 | ||
Smoking history | 0.120 | 0.245 | |||||
None | 245 (64.6) | 1.000 | ? | 1.000 | ? | ||
Yes | 134 (35.4) | 0.459 | 0.172?1.226 | 0.662 | 0.330?1.327 | ||
Alcohol history | 0.768 | 0.109 | |||||
None | 286 (75.5) | 1.000 | ? | 1.000 | ? | ||
Yes | 93 (24.5) | 1.159 | 0.434?3.099 | 1.805 | 0.876?3.722 | ||
Clinical T stage | 0.133 | 0.017 | |||||
T1 | 220 (58.0) | 1.000 | ? | 1.000 | ? | ||
T2?3 | 159 (42.0) | 1.845 | 0.830?4.101 | 2.118 | 1.143?3.926 | ||
Clinical N stage | 0.895 | 0.965 | |||||
N0 | 313 (82.6) | 1.000 | ? | 1.000 | ? | ||
N1 | 63 (16.6) | 0.649 | 0.192?2.189 | 0.798 | 0.334?1.910 | ||
N2 | 3 (0.8) | 7.038 | 0.926?53.499 | 3.652 | 0.498?26.802 | ||
Pathological T stage | 0.119 | 0.005 | |||||
T1a | 78 (20.6) | 1.000 | ? | 1.000 | ? | ||
T1b | 263 (69.4) | 2.646 | 0.616?11.377 | 4.578 | 1.095?19.146 | ||
T2 | 38 (10.0) | 3.659 | 0.670?19.997 | 7.550 | 1.568?36.362 | ||
LVI | 0.646 | 0.623 | |||||
Negative | 357 (94.2) | 1.000 | ? | 1.000 | ? | ||
Positive | 22 (5.8) | 1.404 | 0.331?5.957 | 1.343 | 0.414?4.352 | ||
Tumor diameter | 0.087 | 1.140 | |||||
≤2.0 cm | 148 (39.1) | 1.000 | ? | 1.000 | ? | ||
>2.0 cm | 231 (60.9) | 1.985 | 0.905?4.353 | 1.140 | 0.611?2.127 | ||
Postoperative complications | 0.116 | 0.511 | |||||
None | 224 (59.1) | 1.000 | ? | 1.000 | ? | ||
Clavien-Dindo classification Ⅰ?Ⅱ | 76 (20.1) | 1.129 | 0.360?3.561 | 1.263 | 0.557?2.848 | ||
Clavien-Dindo classification Ⅲ?Ⅴ | 79 (20.8) | 1.973 | 0.808?4.497 | 1.265 | 0.607?2.838 | ||
No. of dissected lymph nodes | 0.011 | 0.001 | |||||
<15 | 150 (39.6) | 1.000 | ? | 1.000 | ? | ||
≥15 | 229 (60.4) | 0.301 | 0.120?0.758 | 0.324 | 0.162?0.647 |
Tab 2 Univariate analysis of risk factors on OS and DFS
Variable | n (%) | OS | DFS | ||||
---|---|---|---|---|---|---|---|
HR | 95%CI | P value | HR | 95%CI | P value | ||
Age | 0.025 | 0.211 | |||||
<65 year | 203 (53.6) | 1.000 | ? | 1.000 | ? | ||
≥65 year | 176 (46.4) | 2.521 | 1.124?5.656 | 1.480 | 0.801?2.734 | ||
Gender | 0.092 | 0.127 | |||||
Male | 300 (79.2) | 1.000 | ? | 1.000 | ? | ||
Female | 79 (20.8) | 0.179 | 0.024?1.324 | 0.448 | 0.159?1.258 | ||
Comorbidity | 0.502 | 0.821 | |||||
None | 310 (81.8) | 1.000 | ? | 1.000 | ? | ||
Yes | 69 (18.2) | 1.400 | 0.524?3.738 | 1.098 | 0.487?2.479 | ||
Smoking history | 0.120 | 0.245 | |||||
None | 245 (64.6) | 1.000 | ? | 1.000 | ? | ||
Yes | 134 (35.4) | 0.459 | 0.172?1.226 | 0.662 | 0.330?1.327 | ||
Alcohol history | 0.768 | 0.109 | |||||
None | 286 (75.5) | 1.000 | ? | 1.000 | ? | ||
Yes | 93 (24.5) | 1.159 | 0.434?3.099 | 1.805 | 0.876?3.722 | ||
Clinical T stage | 0.133 | 0.017 | |||||
T1 | 220 (58.0) | 1.000 | ? | 1.000 | ? | ||
T2?3 | 159 (42.0) | 1.845 | 0.830?4.101 | 2.118 | 1.143?3.926 | ||
Clinical N stage | 0.895 | 0.965 | |||||
N0 | 313 (82.6) | 1.000 | ? | 1.000 | ? | ||
N1 | 63 (16.6) | 0.649 | 0.192?2.189 | 0.798 | 0.334?1.910 | ||
N2 | 3 (0.8) | 7.038 | 0.926?53.499 | 3.652 | 0.498?26.802 | ||
Pathological T stage | 0.119 | 0.005 | |||||
T1a | 78 (20.6) | 1.000 | ? | 1.000 | ? | ||
T1b | 263 (69.4) | 2.646 | 0.616?11.377 | 4.578 | 1.095?19.146 | ||
T2 | 38 (10.0) | 3.659 | 0.670?19.997 | 7.550 | 1.568?36.362 | ||
LVI | 0.646 | 0.623 | |||||
Negative | 357 (94.2) | 1.000 | ? | 1.000 | ? | ||
Positive | 22 (5.8) | 1.404 | 0.331?5.957 | 1.343 | 0.414?4.352 | ||
Tumor diameter | 0.087 | 1.140 | |||||
≤2.0 cm | 148 (39.1) | 1.000 | ? | 1.000 | ? | ||
>2.0 cm | 231 (60.9) | 1.985 | 0.905?4.353 | 1.140 | 0.611?2.127 | ||
Postoperative complications | 0.116 | 0.511 | |||||
None | 224 (59.1) | 1.000 | ? | 1.000 | ? | ||
Clavien-Dindo classification Ⅰ?Ⅱ | 76 (20.1) | 1.129 | 0.360?3.561 | 1.263 | 0.557?2.848 | ||
Clavien-Dindo classification Ⅲ?Ⅴ | 79 (20.8) | 1.973 | 0.808?4.497 | 1.265 | 0.607?2.838 | ||
No. of dissected lymph nodes | 0.011 | 0.001 | |||||
<15 | 150 (39.6) | 1.000 | ? | 1.000 | ? | ||
≥15 | 229 (60.4) | 0.301 | 0.120?0.758 | 0.324 | 0.162?0.647 |
Variable | n (%) | OS | DFS | ||||
---|---|---|---|---|---|---|---|
HR | 95% CI | P value | HR | 95% CI | P value | ||
Age | 0.014 | ||||||
<65 year | 203 (53.6) | 1.000 | ? | ||||
≥65 year | 176 (46.4) | 2.800 | 1.231?6.367 | ||||
Gender | 0.053 | ||||||
Male | 300 (79.2) | 1.000 | ? | ||||
Female | 79 (20.8) | 0.138 | 0.019?1.028 | ||||
Pathological T stage | |||||||
T1a | 78 (20.6) | 1.000 | ? | 1.000 | ? | ||
T1b | 263 (69.4) | 2.497 | 0.579?10.765 | 0.220 | 3.986 | 0.943?16.850 | 0.060 |
T2 | 38 (10.0) | 3.235 | 0.564?18.556 | 0.188 | 5.239 | 0.975?28.142 | 0.053 |
Clinical T stage | 0.040 | ||||||
T1 | 220 (58.0) | 1.000 | ? | ||||
T2-3 | 159 (42.0) | 2.096 | 1.036?4.239 | ||||
Tumor diameter | 0.090 | ||||||
≤2.0 cm | 148 (39.1) | 1.000 | ? | ||||
>2.0 cm | 231 (60.9) | 2.053 | 0.895?4.710 | ||||
No. of dissected lymph nodes | 0.007 | 0.000 | |||||
≥15 | 229 (60.4) | 1.000 | ? | 1.000 | ? | ||
<15 | 150 (39.6) | 3.569 | 1.408?9.044 | 3.652 | 1.811?7.361 |
Tab 3 Multivariate analysis of independent risk factors on OS and DFS
Variable | n (%) | OS | DFS | ||||
---|---|---|---|---|---|---|---|
HR | 95% CI | P value | HR | 95% CI | P value | ||
Age | 0.014 | ||||||
<65 year | 203 (53.6) | 1.000 | ? | ||||
≥65 year | 176 (46.4) | 2.800 | 1.231?6.367 | ||||
Gender | 0.053 | ||||||
Male | 300 (79.2) | 1.000 | ? | ||||
Female | 79 (20.8) | 0.138 | 0.019?1.028 | ||||
Pathological T stage | |||||||
T1a | 78 (20.6) | 1.000 | ? | 1.000 | ? | ||
T1b | 263 (69.4) | 2.497 | 0.579?10.765 | 0.220 | 3.986 | 0.943?16.850 | 0.060 |
T2 | 38 (10.0) | 3.235 | 0.564?18.556 | 0.188 | 5.239 | 0.975?28.142 | 0.053 |
Clinical T stage | 0.040 | ||||||
T1 | 220 (58.0) | 1.000 | ? | ||||
T2-3 | 159 (42.0) | 2.096 | 1.036?4.239 | ||||
Tumor diameter | 0.090 | ||||||
≤2.0 cm | 148 (39.1) | 1.000 | ? | ||||
>2.0 cm | 231 (60.9) | 2.053 | 0.895?4.710 | ||||
No. of dissected lymph nodes | 0.007 | 0.000 | |||||
≥15 | 229 (60.4) | 1.000 | ? | 1.000 | ? | ||
<15 | 150 (39.6) | 3.569 | 1.408?9.044 | 3.652 | 1.811?7.361 |
1 | Rice TW, Kelsen D, Blackstone EH, et al. Esophagus and esophagogastric junction[M]//Amin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual. 8th ed. Springer, 2017: 185-202. |
2 | Rice TW, Chen LQ, Hofstetter WL, et al. Worldwide Esophageal Cancer Collaboration: pathologic staging data.[J] Dis Esophagus, 2016,29(7):724-33. |
3 | Rice TW, Ishwaran H, Hofstetter WL, et al. Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals[J]. Dis Esophagus, 2016, 29(8): 897-905. |
4 | Rice TW, Ishwaran H, Blackstone EH, et al. Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals[J]. Dis Esophagus, 2016, 29(8): 913-919. |
5 | Tachimori Y, Ozawa S, Numasaki H, et al. Comprehensive registry of esophageal cancer in Japan, 2012[J]. Esophagus, 2019, 16(3): 221-245. |
6 | Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6 336 patients and results of a survey[J]. Ann Surg, 2004, 240(2): 205-213. |
7 | Tachimori Y. Total mesoesophageal esophagectomy[J]. Chin Med J, 2014, 127(3): 574-579. |
8 | Tsunoda S, Shinohara H, Kanaya S, et al. Mesenteric excision of upper esophagus: a concept for rational anatomical lymphadenectomy of the recurrent laryngeal nodes in thoracoscopic esophagectomy[J]. Surg Endosc, 2020, 34(1): 133-141. |
9 | Minashi K, Nihei K, Mizusawa J, et al. Efficacy of endoscopic resection and selective chemoradiotherapy for stage Ⅰ esophageal squamous cell carcinoma[J]. Gastroenterology, 2019, 157(2): 382-390.e3. |
10 | Yang Y, Su Y, Zhang X, et al. Esophagectomy versus definitive chemoradiotherapy for patients with clinical stage N0 and pathological stage T1b esophageal squamous cell carcinoma after endoscopic submucosal dissection: study protocol for a multicenter randomized controlled trial (Ad-ESD Trial)[J]. Trials, 2020, 21(1): 603. |
11 | Wang J, Zhu XN, Zhu LL, et al. Efficacy and safety of endoscopic submucosal tunnel dissection for superficial esophageal squamous cell carcinoma and precancerous lesions[J]. World J Gastroenterol, 2018, 24(26): 2878-2885. |
12 | Suzuki G, Yamazaki H, Aibe N, et al. Endoscopic submucosal dissection followed by chemoradiotherapy for superficial esophageal cancer: choice of new approach[J]. Radiat Oncol, 2018, 13(1): 246. |
13 | Kawaguchi G, Sasamoto R, Abe E, et al. The effectiveness of endoscopic submucosal dissection followed by chemoradiotherapy for superficial esophageal cancer[J]. Radiat Oncol, 2015, 10: 31. |
14 | Akutsu Y, Uesato M, Shuto K, et al. The overall prevalence of metastasis in T1 esophageal squamous cell carcinoma: a retrospective analysis of 295 patients[J]. Ann Surg, 2013, 257(6): 1032-1038. |
15 | Yoshida N, Yamamoto H, Baba H, et al. Can minimally invasive esophagectomy replace open esophagectomy for esophageal cancer? Latest analysis of 24 233 esophagectomies from the Japanese national clinical database[J]. Ann Surg, 2020, 272(1): 118-124. |
[1] | Ren-yan WU, Xiao-lin GUO, Deng-li HONG, Lei CHEN. Identification of potential therapeutic target genes in pediatric acute leukemia of ambiguous lineage based on bioinformatics analysis [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(3): 320-327. |
[2] | Xiao-jun ZHAO, Zhi-gang QIAO, Ting-yu LIANG, Yan-ling AN. Expression of breast cancer susceptibility gene 1 protein in brain gliomas and its influence on the sensitivity of temozolomide [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(1): 118-122. |
[3] | CHEN Si, LIU Chun-liang, ZHAO Qian, SUN Hai-peng, LIU Yun-xia. Identification of hub genes and key pathways in breast cancersurvival-based bioinformatics analysis [J]. , 2020, 40(3): 294-. |
[4] | LI Qian, GAO Jing-ze, LI Yun, SONG Kun, SHEN Qian-cheng. Bioinformatics analysis of esophageal squamous cell carcinoma genomic chip and prediction of targeted drug [J]. , 2020, 40(2): 194-. |
[5] | ZENG Qun-xiong1, 2, DENG Jun1, 2, SHEN Nan1, 2. Study the regulatory role of STAT3 on CD8+ T cells using adoptive transfer model in immunodeficient mice [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(11): 1437-1446. |
[6] | LIN Xin-yan1, ZHOU Wen-jie1, WANG Feng2, HUANG Wei2, WANG Zhen3,QU Xing-zhou3#, WU Yi-qun1#. Functional reconstruction of maxillectomy defect with zygomatic implant [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(10): 1382-1387. |
[7] | WANG Yang-yang1, ZHENG Xiao2, ZHU Chun-chao1, LIU Qiang3, ZHANG Zi-zhen1, ZHAO En-hao1. Analysis of Tim-3/Gal-9 expression and T cell infiltration in adenocarcinoma of the esophagogastric junction [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(06): 847-855. |
[8] | YANG Xue-tao, WANG Xiao-wen, WU Qing-chen. Effects of miR-760 targeting c-Myc on biological characteristics of human esophageal squamous cell carcinoma TE-10 cells [J]. , 2019, 39(11): 1268-. |
[9] | JI Jia-wei1, 2, WANG Rui1, LUO Ting-ting4, XU Meng-sha1, GUO Xiao-kui1, HU Fu-pin3, LI Min2, HE Ping1. Characterization and genome sequencing of SH-Ab 15599, a novel bacteriophage targeting carbapenem-resistant Acinetobacter baumannii [J]. , 2018, 38(11): 1283-. |
[10] | HUANG Lei-jie, LIU Xiao-liang, ZHU Rui, LIN Fang-qi, QIN Jin-hong, HE Ping, GUO Xiao-kui, ZHAO Wei. Isolation and characterization of bacteriophage against extended-spectrum β-lactamase-producing Escherichia coli strains [J]. , 2017, 37(8): 1069-. |
[11] | LIU Zhao*, ZHANG Yun-xiang*, WANG Li-ning*, XIA Zheng, MAO Yuan-fei, ZHAO Hui-jin, YOU Jian-hua, YU Yang, ZHAO Yu-bing, REN Yu-hong, LI Ya, WANG Yan, CHEN Qiu-sheng, LI Jun-min#, CHEN Yu# . A phase IV study of homoharringtonine, cytarabine, aclacinomycin and G-CSF (HCAG) regimen compared with traditional IA regimen in the treatment of newly diagnosed elderly acute myeloid leukemia patients [J]. , 2017, 37(8): 1100-. |
[12] | XU Xin, MA Xiu-mei, ZHOU Di, BAI Yong-rui . Effects of the status of lymph nodes metastasis on the prognosis of postoperative radiotherapy for patients with locally advanced esophageal squamous cell carcinoma#br# [J]. , 2017, 37(10): 1407-. |
[13] | ZHI Ye, LUO Ting-ting, WANG Rui, FENG Xi-jia, LIU Ke, SHI Chen-kun, WANG Lu-lu, HU Fu-pin, HE Ping. Characterization and genomic analysis of bacteriophage SH-Kp152234 infecting extensively drug-resistant Klebsiella pneumonia [J]. , 2017, 37(03): 273-. |
[14] | BIAN Zhi-xiang, CHEN Pei-hua, GU Hui-yi, HU Chun, PAN Yu. Comparison of the prognosis in patients with diabetic nephropathy undergoing different phases of hemodialysis [J]. , 2016, 36(06): 875-. |
[15] | LIU Shen-zha, HAN Guo-hu, ZHOU Yue-peng, MAO Chao-ming, CHEN De-yu. Study on mechanisms of the apoptosis in TE-1 cells of esophageal squamous cell carcinoma induced by EGCG combined with radiotherapy [J]. , 2016, 36(04): 487-. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||